Literature DB >> 9479858

Functions of alpha 4- and beta 7-integrins in hematopoiesis, lymphocyte trafficking and organ development.

N Wagner1, W Müller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9479858     DOI: 10.1007/978-3-642-71987-5_2

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  6 in total

1.  Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates alpha(4) integrins.

Authors:  Yoichi Imai; Eun Jeong Park; Dan Peer; António Peixoto; Guiying Cheng; Ulrich H von Andrian; Christopher V Carman; Motomu Shimaoka
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

2.  Effect of α4β7 blockade on intestinal lymphocyte subsets and lymphoid tissue development.

Authors:  Caihong Wang; Elyse K Hanly; Leroy W Wheeler; Manreet Kaur; Keely G McDonald; Rodney D Newberry
Journal:  Inflamm Bowel Dis       Date:  2010-10       Impact factor: 5.325

3.  Alpha4beta7/MAdCAM-1 interactions play an essential role in transitioning cryptopatches into isolated lymphoid follicles and a nonessential role in cryptopatch formation.

Authors:  Caihong Wang; Jacquelyn S McDonough; Keely G McDonald; Conway Huang; Rodney D Newberry
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

4.  Leukocyte integrin α4β7 associates with heat shock protein 70.

Authors:  Yih-Chih Chan; David R Greenwood; Yi Yang; Euphemia Leung; Geoffrey W Krissansen
Journal:  Mol Cell Biochem       Date:  2015-08-11       Impact factor: 3.396

5.  Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.

Authors:  Susan Friend; Sandra Richman; Gary Bloomgren; Lynda M Cristiano; Madé Wenten
Journal:  BMC Neurol       Date:  2016-08-24       Impact factor: 2.474

6.  AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.

Authors:  Hiroyuki Fukase; Toshifumi Kajioka; Ichiro Oikawa; Naoki Ikeda; Hidetoshi Furuie
Journal:  Br J Clin Pharmacol       Date:  2020-01-28       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.